Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia

IF 2.6 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Journal of Clinical Laboratory Analysis Pub Date : 2024-10-10 DOI:10.1002/jcla.25111

Bekele Sharew, Ayenew Berhan, Andargachew Almaw, Mulat Erkihun, Tegenaw Tiruneh, Teklehaimanot Kiros, Yenealem Solomon, Mitikie Wondmagegn, Etenesh Wondimu, Abay Teshager, Simegnew Bihonegn, Mihret Tilahun, Birhanu Getie

{"title":"Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia","authors":"Bekele Sharew, Ayenew Berhan, Andargachew Almaw, Mulat Erkihun, Tegenaw Tiruneh, Teklehaimanot Kiros, Yenealem Solomon, Mitikie Wondmagegn, Etenesh Wondimu, Abay Teshager, Simegnew Bihonegn, Mihret Tilahun, Birhanu Getie","doi":"10.1002/jcla.25111","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Tuberculosis (TB) is a preventable and treatable disease leading to the second death globally. The evolution of drug resistance in <i>Mycobacterium tuberculosis</i> (MTB), particularly rifampicin resistance (RR), has hampered TB control efforts. Thus, this study aimed to provide information regarding the magnitude of MTB and rifampicin resistance among patients tested using the GeneXpert method.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective analysis was carried out at DTCSH. The study included TB registration logbook data from all patients who visited the hospital and were tested for MTB with the Xpert MTB/RIF assay from 2017 to 2024. The laboratory-based data were entered, cleaned, and analyzed using SPSS version 26 software. Multilogistic regression analysis was employed, and a <i>p</i> value ≤ 0.05 was considered statistically significant.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 12,981 patient results were included, of which 8.9% (1160/12,981) were MTB-positive and 7.1% (82/1160) were RR. Individuals aged 15–29 years (AOR = 2.13; 95% CI = 1.55–2.93, <i>p</i> < 0.001), living in rural areas (AOR = 1.23; 95% CI = 1.08–1.41, <i>p</i> = 0.003), and HIV+ (AOR = 1.79; 95% CI = 1.48–2.33, <i>p</i> < 0.001) had a higher risk of developing tuberculosis. While RR was identified in 63.4% (52/82) of new, 24.4% (20/82) of re-treated, and 12.2% (10/82) of failed presumptive TB patients.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In this study, MTB and RR trends were high. Productive age groups, rural populations, and HIV patients were at risk. To lessen the burden of this contagious and fatal disease, it is recommended to increase early diagnosis of drug-resistant TB and enhance infection control.</p>\n </section>\n </div>","PeriodicalId":15509,"journal":{"name":"Journal of Clinical Laboratory Analysis","volume":"38 22","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcla.25111","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Laboratory Analysis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcla.25111","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Tuberculosis (TB) is a preventable and treatable disease leading to the second death globally. The evolution of drug resistance in Mycobacterium tuberculosis (MTB), particularly rifampicin resistance (RR), has hampered TB control efforts. Thus, this study aimed to provide information regarding the magnitude of MTB and rifampicin resistance among patients tested using the GeneXpert method.

Methods

A retrospective analysis was carried out at DTCSH. The study included TB registration logbook data from all patients who visited the hospital and were tested for MTB with the Xpert MTB/RIF assay from 2017 to 2024. The laboratory-based data were entered, cleaned, and analyzed using SPSS version 26 software. Multilogistic regression analysis was employed, and a p value ≤ 0.05 was considered statistically significant.

Results

A total of 12,981 patient results were included, of which 8.9% (1160/12,981) were MTB-positive and 7.1% (82/1160) were RR. Individuals aged 15–29 years (AOR = 2.13; 95% CI = 1.55–2.93, p < 0.001), living in rural areas (AOR = 1.23; 95% CI = 1.08–1.41, p = 0.003), and HIV+ (AOR = 1.79; 95% CI = 1.48–2.33, p < 0.001) had a higher risk of developing tuberculosis. While RR was identified in 63.4% (52/82) of new, 24.4% (20/82) of re-treated, and 12.2% (10/82) of failed presumptive TB patients.

Conclusion

In this study, MTB and RR trends were high. Productive age groups, rural populations, and HIV patients were at risk. To lessen the burden of this contagious and fatal disease, it is recommended to increase early diagnosis of drug-resistant TB and enhance infection control.

Abstract Image

查看原文本刊更多论文

使用 GeneXpert MTB/RIF 检测法检测埃塞俄比亚西北部 Debre Tabor 综合专科医院肺结核病例的利福平耐药 rpoB 基因。

背景：结核病（TB）是一种可预防、可治疗的疾病，是全球第二大死亡病例。结核分枝杆菌（MTB）耐药性的演变，特别是利福平耐药性（RR），阻碍了结核病的控制工作。因此，本研究旨在提供有关使用 GeneXpert 方法检测的患者中 MTB 和利福平耐药性程度的信息：方法：在 DTCSH 进行了一项回顾性分析。研究包括2017年至2024年期间到医院就诊并接受Xpert MTB/RIF检测的所有患者的结核病登记日志数据。实验室数据使用 SPSS 26 版软件进行输入、清理和分析。采用多逻辑回归分析，P值≤0.05为具有统计学意义：共纳入 12981 例患者，其中 MTB 阳性患者占 8.9%（1160/12981），RR 患者占 7.1%（82/1160）。15-29 岁人群（AOR = 2.13；95% CI = 1.55-2.93，P 结论：MTB 和 RR 阳性率与年龄有关：在这项研究中，MTB 和 RR 呈上升趋势。生产年龄组、农村人口和艾滋病毒感染者面临风险。为了减轻这种传染性致命疾病的负担，建议增加耐药结核病的早期诊断并加强感染控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Laboratory Analysis 医学-医学实验技术

CiteScore

5.60

自引率

7.40%

发文量

584

审稿时长

6-12 weeks

期刊介绍： Journal of Clinical Laboratory Analysis publishes original articles on newly developing modes of technology and laboratory assays, with emphasis on their application in current and future clinical laboratory testing. This includes reports from the following fields: immunochemistry and toxicology, hematology and hematopathology, immunopathology, molecular diagnostics, microbiology, genetic testing, immunohematology, and clinical chemistry.